AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05184244 — intervention group
Intervention type: OTHER
Intervention: Activity Limitation Assessment
Description: The ACTIVLIM-CP scale evaluates the global activity performance and combined movements of the body.
Study NCT00775424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-B
Description: PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
Study NCT00775424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GENEVAX IL-12-4532
Description: GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
Study NCT00775424 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO
Study NCT00775424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 adjuvant
Description: pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
Study NCT05000476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye mask and earplugs
Description: Materials similar to those offered on long commercial flights
Study NCT05000476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nurse Education and Environmental Regulation
Description: providing orientation to the patient (frequent orientation of the patient to the place, time and person), cognitive stimulation (objects such as clocks and calendars in the patient's field of view), reducing noise and light (minimizing monitors and fluid infusion pump alarms at night), providing early mobilization ( passive-active joint movements, sitting and walking in bed), reducing social deprivation (receiving visitors, telephone calls)
Study NCT02588443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO70097890
Study NCT02588443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Study NCT02588443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study NCT06571695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomic Long Head of Biceps Tensioning Technique
Description: The standard mini-open subpectoral approach will be made. The myotendinous junction of the long head of the biceps tendon and its location within the intertubercular groove will be marked using electrocautery. The surgeon will then turn to the glenohumeral joint and perform the biceps tenotomy.The long head of the biceps tendon will be retrieved.The tendon is tagged with a running, locking number 2 fiberwire suture at the mid substance of the myotendinous junction using the previously made electrocautery marks to set the tension. The tendon is shortened. The sutures from the biceps are passed through the Arthrex cortical button.The pectoralis major tendon is retracted and 2 centimeters proximal to the distal insertion a unicortical bone tunnel is drilled in the bicipital groove with a 3.2 millimeter drill.The wound is irrigated and the biceps button is threaded into this tunnel and then flipped.The suture is tensioned, securing the biceps against the groove
Study NCT06571695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Long Head of Biceps Tensioning Technique
Description: Diagnostic arthroscopic shoulder scope will occur to assess the long head of the biceps for tendinopathy. Tenotomy will occur at the junction of the supraglenoid tubercle with arthroscopic scissors. Subsequent tensioning and tenodesis will be based on surgeon's preference
Study NCT03027128 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK™ for Infusion
Description: haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
Study NCT03786211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IANB by the guide of Panoramic
Description: IANB will be injected by the guide of panoramic radiograph
Study NCT03786211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IANB by the guide of Panoramic
Description: IANB will be injected by the guide of panoramic radiograph
Study NCT03786211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IANB without the guide of Panoramic
Description: IANB will be injected without the guide of panoramic radiograph, in the routine way.
Study NCT03786211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IANB without the guide of Panoramic
Description: IANB will be injected without the guide of panoramic radiograph, in the routine way.
Study NCT00609050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Regulated Exercise with Telephone Reinforcement
Description: The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
Study NCT00609050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
Study NCT00609050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Approach
Description: A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
Study NCT04139005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness
Description: The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.
Study NCT04139005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connection
Description: The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.
Study NCT04139005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insight
Description: The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
Study NCT00800579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline
Study NCT00800579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled volume-matched placebo in sterile saline
Study NCT00168415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 100 U up to 6 times during the study depending on the response to treatment
Study NCT05090488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal Health Coaching and Diabetes Education in Group
Description: Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
Study NCT05090488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Health Coaching and Diabetes Education in Group
Description: Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
Study NCT02383277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching of the rib cage muscles
Study NCT02383277 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Rest without stretching (sham)
Study NCT02383277 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Constant load exercise on a bike
Study NCT02383277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Constant load exercise on a bike
Study NCT01833520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ra-223 Dichloride
Description: Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.
Study NCT01328925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days
Study NCT01328925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days
Study NCT01903187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnligHTN Renal Denervation
Description: Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
Study NCT01903187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Renal artery angiogram
Study NCT02333877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skinlink
Description: suture using Skinlink
Study NCT02333877 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nylon
Description: conventional suture using nylon
Study NCT02743520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Lifestar Act III
Description: The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.
Study NCT02834507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT02834507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: Capsules containing nebicapone 75 mg or 150 mg
Study NCT02834507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comtan®
Description: Capsules containing entacapone 200 mg
Study NCT02834507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet®
Description: levodopa/carbidopa (Sinemet®) dose patient used to take
Study NCT02834507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet®
Description: levodopa/carbidopa (Sinemet®) dose patient used to take
Study NCT02834507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sinemet®
Description: levodopa/carbidopa (Sinemet®) dose patient used to take
Study NCT04208789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid Molecular Drug-Resistant Tuberculosis Test
Description: GeneXpert MTB/RIF assay is a nucleic acid amplification (NAA) test which simultaneously detects DNA of Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) (i.e. mutation of the rpoB gene) in less than two hours. This system integrates and automates sample processing, nucleic acid amplification, and detection of the target sequences. The primers in the XpertMTB/RIF assay amplify a portion of the rpoB gene containing the 81 base pair core region. The probes are able to differentiate between the conserved wild-type sequence and mutations in the core region that is associated with rifampicin resistance. The output of this procedure is detected, undetected, or indeterminate.
Study NCT04208789 — intervention group
Intervention type: OTHER
Intervention: Artificial Intelligent Model
Description: The artificial intelligent model is a model that developed from several associated factors with machine learning and deep learning method in order to classify the possibility of drug-resistant tuberculosis. The Artificial neural network will be built using deep learning software.
Study NCT04208789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Drug Susceptibility Test
Description: This procedure uses Löwenstein-Jensen (LJ) medium to determine whether the isolates of M. tuberculosis are susceptible to anti-TB agents. Media containing the critical concentration of the anti-TB agent is inoculated with a dilution of a culture suspension (usually a 10-2 dilution of a MacFarland 1 suspension) and control media without the anti-TB agent is inoculated with usually a 10-4 dilution of a MacFarland 1 suspension. Growth (i.e. a number of colonies) on the agent-containing media is compared to the growth on the agent-free control media. The ratio of the number of colonies on the medium containing the anti-TB agent to the number of colonies (corrected for the dilution factor) on the medium without the anti-TB agent is calculated, and the proportion is expressed as a percentage. Provisional results for susceptible isolates may be read after 3-4 weeks of incubation; definitive results may be read after 6 weeks of incubation. Resistance may be reported within 3-4 weeks.
Study NCT02035878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: probiotic intervention: 400mg of probiotic capsule
Study NCT02035878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study NCT00546637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Fesoterodine 4mg or 8mg
Study NCT00546637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01606930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Primer Tool
Description: The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs.
Study NCT01293721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-magnitude high - frequency vibration treatment
Description: stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
Study NCT04199611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: This is a type of fat removal procedure used in plastic surgery.
Study NCT04199611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liposuction
Description: This is a type of fat removal procedure used in plastic surgery.
Study NCT04199611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This is a psycho-social intervention that aims to improve mental health.
Study NCT04199611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: This is a psycho-social intervention that aims to improve mental health.
Study NCT03369405 — intervention group
Intervention type: OTHER
Intervention: NO intervention, patient records review only
Description: There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
Study NCT03145285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision.
Study NCT01402544 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab
Description: 0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
Study NCT02986399 — intervention group
Intervention type: OTHER
Intervention: Fast track patient pathway
Description: Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
Study NCT01690208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMERALD
Description: Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.~These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule.
Study NCT01690208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment \& explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
Study NCT00653250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
Study NCT00653250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue
Study NCT00653250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: surgery to remove the lung tumor
Study NCT02459353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Study NCT02459353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03266107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracept
Description: Radiofrequency ablation of the basivertebral nerve using the Intracept System
Study NCT03674749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meditation and Hyperbaric Oxygen Treament
Description: Meditation sessions will be combined with hyperbaric oxygen treatment
Study NCT03674749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation and Hyperbaric Oxygen Treament
Description: Meditation sessions will be combined with hyperbaric oxygen treatment
Study NCT03731780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Treatment
Description: Targeting individual caries risk factors
Study NCT03731780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine and Remineralization
Description: chlorhexidine mouth wash and remineralizing agent
Study NCT03731780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control is standard preventive measures (tooth brushing, fluoride tooth paste, interdental cleaning)
Study NCT00694993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1004723
Description: GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
Study NCT00694993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
Study NCT01327898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: empowerment theory-based small group discussion
Description: four small group discussion sessions followed by one individual counseling session
Study NCT01327898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individual resilience counseling
Description: one individual resilience counseling session
Study NCT02454400 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pre-surgery physiotherapy
Description: Physiotherapy guided intervention twice a week for nine weeks. The program includes:~1. Active physiotherapy according to a treatment based classification:~   1. Specific exercises and mobilization~  2. Motor control exercises~  3. Traction~2. Tailor-made general supervised exercise program~3. Behavioral approach to reduce fear avoidance and increase activity level.~4. Standardized information about:~   1. the surgery~  2. post-surgery rehabilitation~  3. to stay active